VICTORIA, BC , Nov. 13, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr.
James A. Helliwell , will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed". The event is scheduled to begin at 8:30 am PT / 11:30 am ET on Friday, November 15, 2024 .
To register to join the complimentary event, please visit Tribe Public at: EPRXNOV1524.TribePublic.com Once registered, participants may begin forwarding their questions for Dr.
Helliwell to Tribe Public at research@tribepublic.com , or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F.
Heerdink, Jr. , will host the event and relay all questions to management. About Eosinophilic Esophagitis Eosinophilic Esophagitis ("EoE") is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food.
According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and preval.